CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...